Open AccessConsenso sobre el tratamiento del síndrome inflamatorio multisistémico asociado a COVID-19
Author(s) -
Gabriela Ensinck,
Gabriela Gregorio,
Rosana M Flores,
Cecilia I Crowe,
Paola Clerico Mosina,
Claudia Curi,
Facundo Jorro Barón,
Guillermo Kohn Loncarica,
Sofía Grinenco,
Carlos Rojas Ríos,
Claudia González,
Vanesa Zaslavsky,
Leonardo De Lillo,
Eduardo Vainstein,
Luis Urrutia
Publication year - 2021
Publication title -
archivos argentinos de pediatría
Language(s) - Spanish
Resource type - Journals
SCImago Journal Rank - 0.236
H-Index - 19
eISSN - 1668-3501
pISSN - 0325-0075
DOI - 10.5546/aap.2021.s198
Subject(s) - medicine , humanities , philosophy
The pandemic caused by the SARS-CoV-2 virus declared by the WHO in March 11th 2020, affects a small number of pediatric patients, who mostly present mild respiratory compromise and favorable evolution. However began to be observed in previously healthy children, an increase in cases defined as "Multisystemic Inflammatory Syndrome" (MIS-C) or "Kawasaki-like" post-COVID 19 (KLC) that evolve to shock and require hospitalization in the Pediatric Intensive Care Unit. MIS-C and KL-C are characterized by fever; signs of inflammation, gastrointestinal symptoms, and cardiovascular dysfunction, associated with sever forms of presentation with higher incidence of hypotension and/or shock. In the laboratory, markers of inflammation, hypercoagulability and myocardial damage are observed. Firstline drug treatment consists of intravenous immunoglobulin plus oral acetylsalicylic acid. A multidisciplinary approach is recommended for an accurate diagnosis and an early and effective treatment, in order to reduce morbidity and mortality.